Welcome to Hmobio!Global leader in active molecules.
Find Your Distributors

Select Your Country or Region

 $ USD

For research purposes only. Not for human experiments
You are here:Home-Inhibitors & Agonists-PI3K/Akt/mTOR Pathway-PIKfyve

Request The Product List ofPIKfyve PIKfyve

PIKfyve, a FYVE finger-containing phosphoinositide kinase, is an enzyme that in humans is encoded by the PIKFYVE gene. The principal enzymatic activity of PIKfyve is to phosphorylate PtdIns3P to PtdIns(3,5)P2. PIKfyve activity is responsible for the production of both PtdIns(3,5)P2 and phosphatidylinositol 5-phosphate (PtdIns5P). PIKfyve is a large protein, containing a number of functional domains and expressed in several spliced forms. By directly binding membrane PtdIns(3)P, the FYVE finger domain of PIKfyve is essential in localizing the protein to the cytosolic leaflet of endosomes. Impaired PIKfyve enzymatic activity by dominant-interfering mutants, siRNA- mediated ablation or pharmacological inhibition causes endosome enlargement and cytoplasmic vacuolation due to impaired PtdIns(3,5)P2 synthesis. Thus, via PtdIns(3,5)P2 production, PIKfyve participates in several aspects of endosome dynamics, thereby affecting a number of trafficking pathways that emanate from or traverse the endosomal system en route to the trans-Golgi network or later compartments along the endocytic pathway.

Cat. No. Product Name CAS No. Information
H7112

YM-201636

 		371942-69-7

YM-201636 is a potent, selective PIKfyve inhibitor with IC50 of 33 nM, does not inhibits type Iiγ/Iα PtdInsP kinases even at 10 uM (p110α IC50=3.3 uM); shows insensitivity against yeast orthologue of PIKfyve, Fab1; significantly decreases the production of PtdIns(3,5)P2 by 80% in serum-starved NIH3T3 cells with no effect on serum-stimulated PKB Ser 473 phosphorylation at 0.8 uM; inhibits basal and insulin-activated 2-deoxyglucose uptake withIC50 of 54 nM; significantly reduces retroviruses budding from cells; blocks the continuous recycling of the tight junction proteins claudin-1 and claudin-2 in MDCK cells.

H7111

AS2795440

 		2241279-48-9

A novel potent, selective, oral PIKfyve inhibitor that selectively decreases c-Rel binding to gene promoters of IL-12p40 and IL-1β, regulates cytokine production through PIKfyve-c-Rel pathway ( IL-12p40 IC50=2 nM); inhibits the production of IL-12p40, IL-6 and IL-1β but not TNFα in activated macrophages or dendritic cells, and expression of IgM-induced MHC class II on B cells; reduces Akt phosphorylation in IFNγ/LPS-stimulated RAW264.7 cells, greatly increases cell size with many small vesicles in the cytoplasm; prevents the development of arthritis in rats.
H7110

AS2677131

 		2171502-44-4

AS2677131(AS 2677131, AS-2677131) is a novel potent, oral PIKfyve inhibitor that selectively decreases c-Rel binding to gene promoters of IL-12p40 and IL-1β, regulates cytokine production through PIKfyve-c-Rel pathway ( IL-12p40 IC50=4 nM); inhibits the production of IL-12p40, IL-6 and IL-1β but not TNFα in activated macrophages or dendritic cells, and expression of IgM-induced MHC class II on B cells; reduces Akt phosphorylation in IFNγ/LPS-stimulated RAW264.7 cells, greatly increases cell size with many small vesicles in the cytoplasm.
H7109

Apilimod

 		541550-19-0

A potent IL-12/IL-23 inhibitor that down-regulates both IL-12 p35 and IL-12/IL-23 p40 at the transcriptional level, and inhibits the production of both IL-12 and IL-23 cytokines (IC50=2 nM); suppresses Th1 but not Th2 immune response in mice; binds to PIKfyve and blocks its phosphotransferase activity (IC50=14 nM), has no activity on PIP4K, PIP5K, mTOR, PI3K and PI4K isoforms; also potently blocks infections by EBOV and MARV in Huh 7, Vero E6 and primary human macrophage cells with IC50 of 10 nM.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 HmoBio. All Rights Reserved. Products are only for research use
沪ICP备2020027822号-1